Related Experiment Videos
Replicating herpes simplex virus vectors for cancer gene therapy
1Department of Microbiology and Immunology, University of British Columbia, 300-6174 University Boulevard, Vancouver, BC, V6T 1Z3, Canada.
Abstract:
Attenuated viral vectors based on herpes simplex virus (HSV) are capable of killing cancer cells directly while sparing normal tissue in animal models of disease. This selective ability is likely due to the evolutionary constraints on the virus to establish lifelong infection in its host without causing destruction of normal tissues. However, extensive experimental animal data show that cancer cells are able to sustain a productive viral infection, which ultimately leads to cell death and tumour regression. Moreover, preliminary results generated in two Phase I clinical studies of modified replicating HSV for the treatment of brain tumours (e.g., glioblastoma multiforme) have been encouraging and suggest that the safety data generated in animals are predictive of human safety. Although much progress has been made in developing oncolytic HSV vectors for clinical use, there is still a long way to go to determine which combinations of virus, surgery, radiation and chemotherapy will provide improved therapy for the control and eradication of a variety of human cancers.
Insights
Attenuated herpes simplex virus (HSV) vectors show promise in selectively killing cancer cells and regressing tumors. Early clinical trials for brain tumors are encouraging, suggesting potential for oncolytic virotherapy in cancer treatment.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Attenuated herpes simplex virus (HSV) vectors demonstrate selective oncolysis in animal models.
- HSV's evolutionary constraints favor lifelong infection without normal tissue destruction, enabling cancer cell targeting.
- Cancer cells support productive viral replication, leading to cell death and tumor regression.
Purpose of the Study:
- To evaluate the potential of attenuated HSV vectors as an oncolytic therapy for cancer.
- To assess the safety and efficacy of modified replicating HSV in preclinical and early clinical settings.
- To explore the therapeutic combinations of oncolytic HSV with existing cancer treatments.
Main Methods:
- Utilizing attenuated viral vectors based on herpes simplex virus (HSV).
- Testing in animal models to demonstrate selective cancer cell killing and tumor regression.
- Conducting Phase I clinical studies for brain tumor treatment.
Main Results:
- Animal models show selective killing of cancer cells by HSV vectors, sparing normal tissues.
- Preliminary Phase I clinical data for brain tumors are encouraging regarding safety.
- Evidence suggests animal safety data predict human safety for modified replicating HSV.
Conclusions:
- Attenuated oncolytic HSV vectors hold significant promise for cancer therapy.
- Early clinical results support the potential of HSV-based virotherapy for brain tumors.
- Further research is needed to optimize combinations of oncolytic HSV with standard therapies for broad cancer eradication.